Please login to the form below

Not currently logged in

AbbVie acquires Syndesi Therapeutics in $1bn deal

The deal will allow AbbVie to access Syndesi’s research into Alzheimer's disease


AbbVie has announced its acquisition of Syndesi Therapeutics, further expanding AbbVie’s neuroscience portfolio.

The deal will allow AbbVie to access Syndesi’s research into the potential treatment of cognitive impairment and other symptoms associated with neurodegenerative and neuropsychiatric disorders, including major depressive disorder and Alzheimer's disease.

AbbVie has been heavily involved in various Alzheimer’s projects, including an amyloid-beta drug the company believes could work against the degenerative disease. However, AbbVie’s R&D team has also been hindered by setbacks, including a decision to scrap a phase 2 tau-focused drug, ABBV-8E12, after failing to record efficacy.

The acquisition further reinforces AbbVie’s neurology pipeline, as four years ago, Syndesi Therapeutics gained the rights to UCB’s synaptic vesicle protein 2A (SV2A) programme, which aims to achieve synaptic efficiency, targeting the communication between neurons in the brain, which – most notably in Alzheimer’s – typically deteriorates as degenerative illnesses progress.

According to the terms of the $1bn agreement, Abbvie will pay Syndesi an upfront payment of $130m, with milestone payments of up to $870m.

Sharing his thoughts on the deal, Tom Hudson, senior vice president, R&D, chief scientific officer, AbbVie, said: "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases."

"With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders."

Speaking on behalf of Syndesi, Jonathan Savidge, chief executive officer, commented: "We have been impressed with the vision of AbbVie's neuroscience R&D team, who share our view on the therapeutic potential of SDI-118 in a range of neurologic diseases."

"It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. Now, as part of AbbVie, the programme is well positioned to move into later stages of clinical development."

Article by
Fleur Jeffries

2nd March 2022

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
The digital-first launch: the key to connected stakeholder experiences?
During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...